Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

被引：0
|
作者：
Velez, L. [1 ,2 ]
Trevino, T. [4 ]
Kopetz, S. [3 ]
Grothey, A. [4 ]
Yaeger, R. [5 ]
Gollerkeri, A. [6 ]
Maharry, K. [6 ]
Tabernero, J. [1 ,2 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Inst Oncol, Barcelona, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Tennessee, West Canc Ctr, Germantown, TN USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Pfizer Inc, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SO-21
引用
收藏
页码：S224 / S225
页数：2
相关论文
共 50 条
  • [1] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)
    Chiu, C-F.
    Yeh, Y-M.
    Yeh, K-H.
    Desai, J.
    Price, T. J.
    Tebbutt, N.
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Gollerkeri, A.
    Maharry, K.
    Kopetz, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1276 - S1276
  • [2] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    [J]. ESMO OPEN, 2021, 6 (06)
  • [3] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
    Aderka, D.
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Golden, A.
    Edwards, M.
    Tabernero, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
  • [4] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    [J]. DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [5] Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study
    Taieb, Julien
    Lonardi, Sara
    Desai, Jayesh
    Folprecht, Gunnar
    Gallois, Claire
    Marques, Eduardo Polo
    Khan, Sadya
    Castagne, Claire
    Wasan, Harpreet
    [J]. CLINICAL COLORECTAL CANCER, 2023, 22 (01) : 59 - 66
  • [6] Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib plus cetuximab ± binimetinib: Subanalysis of BEACON CRC
    Ng, K.
    Ciardiello, F.
    Van Cutsem, E.
    Yaeger, R.
    Yoshino, T.
    Desai, J.
    Wasan, H.
    Alkuzweny, B.
    Zhang, X.
    Tabernero, J.
    Kopetz, S.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S372 - S373
  • [7] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC)
    Desai, Jayesh
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Ciardiello, Fortunato
    Chantrill, Lorraine
    Tebbutt, Niall
    Strickland, Andrew
    Price, Timothy
    Karapetis, Chris
    Murphy, Felicity
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 119 - 120
  • [8] Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC).
    Kopetz, Scott
    Aderka, Dan
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Wasan, Harpreet Singh
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Golden, Adele
    Edwards, Michelle L.
    Tabernero, Josep
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT BINIMETINIB FOR BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER: MANAGEMENT OF ADVERSE EVENTS FROM A RANDOMIZED, 3-ARM, PHASE 3 STUDY VS. THE CHOICE OF EITHER IRINOTECAN OR FOLFIRI PLUS CETUXIMAB (BEACON CRC)
    Trevino, Tracy
    Kopetz, Scott
    Grothey, Axel
    Yaeger, Rona
    Sandor, Victor
    Velez, Lydia
    [J]. ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [10] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    [J]. ESMO OPEN, 2022, 7 (03)
12345